Skip to content

Mechanism of Action of Electroconvulsive Therapy

Mechanism of Action of Electroconvulsive Therapy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04059952
Acronym
MoA-ECT
Enrollment
102
Registered
2019-08-16
Start date
2019-06-28
Completion date
2024-05-31
Last updated
2025-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Depression, Unipolar Depression

Keywords

Electroconvulsive Therapy, Magnetic Resonance Imaging

Brief summary

This is an observational neuroimaging study assessing the effects of ECT on the brains of patients with unipolar and bipolar depression.

Detailed description

This project aims to use functional connectivity magnetic resonance imaging (fcMRI) to study patients with unipolar and bipolar depression receiving ECT. Patients will be scanned before and after a full course of ECT and clinical measures for depression severity and memory will be obtained at the same times.The project has the following aims and hypothesis: (1) to determine the therapeutic antidepressant mechanism of action of ECT at the circuit level (2) to determine the mechanism of action of iatrogenic amnesia caused by ECT at the circuit level (3) to study the use of fcMRI as a state biomarker for depression (4) to study the use of fcMRI as a predictor of response for depression.

Interventions

DEVICEElectroconvulsive Therapy

Electrical currents are passed through the brain to intentionally trigger a controlled seizure in order to produce a therapeutic change in neuro-chemistry and circuitry.

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Males and Females Between Ages of 18 and 65 * Diagnosis of Major Depressive Disorder without Psychotic Features or Bipolar I/II * Requiring ECT Treatment as Part of Psychiatric Care

Exclusion criteria

* Comorbid diagnoses of Major Depressive Disorder with Psychotic Features, Schizoaffective Disorder, Schizophrenia or Dementia * History of Psychosis * Substance Use Disorder (Abuse or Dependence) with Active Use Within Last 6 Months * Severe or Unstable Medical Illness * Medical Contraindication to Anesthesia or ECT (e.g., Recent Myocardial Infarction)

Design outcomes

Primary

MeasureTime frameDescription
Changes in Functional Connectivity of Key NodesThrough Treatment Completion, Average of 2 MonthsMeasured by Magnetic Resonance Imaging, Key Nodes include Subgenual Cingulate, Dorsal Anterior Cingulate, Nucleus Accumbens, Hippocampus, Amygdala and Dorsolateral Prefrontal Cortex

Secondary

MeasureTime frameDescription
Changes in Functional Connectivity of Memory CircuitsThrough Treatment Completion, Average of 2 MonthsMeasured by Magnetic Resonance Imaging, Memory Circuits Include Hippocampus and Dorsolateral Prefrontal Memory Hubs

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026